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Summary
Oral contraceptives and hormone replacement therapy are used by
hundreds of millions of women worldwide. Since the early 1960s it is
known that female hormones increase the risk of venous thrombosis,
myocardial infarction and stroke. This risk is still present with current
low-dose oral contraceptives and, even though in absolute terms the
risk is small, oral contraceptives form the major cause of thrombotic
disease in young women. The risk is higher during the first year of use
(up to l per 1000 per year), with the use of desogestrel- or gestodene-
containing oral contraceptives ("third generation progestogens") and
among women with a prothrombotic predispositon. Hormone replace-
ment therapy increases the risk of venous thrombosis, while results of
randomised trials so far do not substantiate the expectation of a bene-
ficial effect on the risk of arterial cardiovascular disease. First results
are emerging that specific subgroups of women, with prothrombotic or
other abnormalities, may be at risk. especially during the first years of
use of hormone Substitution.
Introduction
Symptomatology and Epidemiology
Venous thrombosis has an annual incidence of 1-3 per 1000 indivi-
duals per year (1.2). It is uncommon in young individuals and becomes
more frequent with advancing age (1). It mostly manifests in the deep
veins of the leg, but may occur in other sites, such äs the upper extrem-
ities, cerebral sinus, liver and portal veins or retinal veins. Embolisa-
tion occurs when parts of the clot dislodge and are transported by the
blood flow, usually through the heart to the vasculature of the lungs (3).
Thrombosis is a serious disorder; it can result in fatal pulmonary
embolism. Estimates of the case fatality rate of venous thrombosis vary
widely. Two large natural history studies (2, 4) found that 12-25 per-
cent of all events of venous thrombosis were fatal, while recent trials
found much lower figures, around 1-3 percent (5-10 percent for pulmo-
nary embolism) (5-7). This wide ränge may be caused by the inclusion
of thrombosis äs secondary cause of death in the studies with a high
estimate, and the selection of patients with a good prognosis in clinical
trials. The Worcester study also showed that the case fatality rate was
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highly dependent on age. with a low mortality among those aged fön·.
or less at the time of thrombosis (2). The postthrombotic syndroirc
leads to chronic morbidity in a substantial number of patients (8).
Risk factors for thrombosis are usually divided into genetic an,<
acquired factors. Mechanistically, they fall into three groups of causc-
according to Virchow: reduced blood flow, changes in the vessel \u:
and changes in the composition of the blood (9). For venous thront
sis, the first (stasis) and third group (changes in blood coagulabilm
appear most prominent, while for arterial disease, factors that äffe-
the vessel wall, i.e. promote atherosclerosis, are most relevant. Th:
genetic risk factors for venous thrombosis are all associated with ehr
ges in the blood composition, while acquired causes are either asxv
ated with decreased flow, i.e., immobilisation, paralysis, surger.
plaster casts, or related to blood coagulation, such äs the lupus am-
coagulant, pregnancy, oral contraception, malignancies. Table 11κ·
the main risk factors for venous thrombosis.
Hormones and Venous Thrombosis
The first report of venous thrombosis related to the use of oral cw
traceptives was in 1961, when Jordan wrote about a nurse whoto:
developed pulmonary embolism. shortly after starting a course«ι
combined oral contraceptive containing 100 μg mestranol forthetit£
ment of endometriosis (10). It has subsequently been shown that»
trogens increase the risk of thrombosis in women, when used äs oa
contraceptive or äs hormone replacement therapy in postmenopaa«*'
women (11-13). Oestrogens also increase the risk of thrombosis in m
which became apparent when they were tried in the treatment of at·
nary disease (14) äs well äs in the course of sex change treatmeni > i:
More recently, it has been demonstrated that not only oestrogenv fc
also progestogens in combination oral contraceptives may increarf &
risk of thrombosis (16-18), while progestin-only preparations nia) ̂
increase the risk of thrombosis (19,20).
Oral Contraceptives
Compoution
Most oral contraceptive drug preparations supply an oestrosenani»
progestogen. In the majority of oral contraceptives used, these are K* j
contained in each pill (monophasic preparations), and a womanU** j
the same combination for three weeks, followed by a pill-fr« **j
during which a withdrawal bleeding takes place. The mode of actK<* j
the suppression of the ovulation process through the combined ad*j
of the progestogen and to a lesser extent the oestrogen compouw * J
progestogen compound suppresses luteinizing hormone (LHi a* J
LH-surge, while the oestrogens suppress follicle stimulating l
(FSH). Since the amount of oestrogen has been minimised, o***
follicle development can be detected during pill use. The majoriorr**J
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asc of-trogen component in the pill is to prevent spotting and break-
äwiuch bleedmgs by organizing the endometnum. In biphasic and
mptuMO combmations. the content of the pills taken during one cycle
ianev w ith more oestrogens in the early phase of the cycle, and more
froiMogens in the later phase of the cycle. Some preparations only
conuin a progestogen, and are mainly used when oestrogens are con-
szdered contra-indicated; they cause a higher frequency of spotting and
bctakthrough bleedings leading to a lower compliance. Most oral con-
flseeptives. have a 1% failure rate with complete compliance. Since pro-
ztsioaens also affect the viscosity of cervical mucus, even ovulations
dui do occur (escape ovulation) during perfect use seldomly lead to
jwgnancy. Reliability of progestogen-only oral contraceptives is prob-
»bi) similar to those for combined oral contraceptives (21).
Naturally oceumng sex steroids are inactive when taken orally.
Hcnce, early research in the 1930s focussed on manufacturing slightly
äitered hormones that could be taken orally. Adding an ethinyl group at
die 17-position of oestradiol led to the potent oral oestrogen ethinyl-
totradiol. which was subsequently used in oral contraceptives.
Mestranol is the 3-methylether of ethinyloestradiol, which is rapidly
tnetabohsed into ethinyloestradiol, and has also been used in oral con-
(ncepti\es.
OralK active progestogens are predominantly based on the synthetic
SMtweron derivative ethisterone. The progestogens in this class, which
se all ihose currently used in oral contraceptives, are called 19-nor-
(Merones There is no formal classification System of progestogens and
they are usually grouped into "generations" based on when they were
tir>t produced. First generation progestogens include norethisterone,
iweih\nodrel, lynestrenol and ethynodiolacetate. The second generation
includes norgestrel, levonorgestrel and norgestrione. The third genera-
öon includes desogestrel, gestodene and norgestimate. Although, tem-
pordlh, norgestimate should be included in the third generation group,
11 is also often classified among second-generation progestogens, since
aftcruptake it is partly converted to levonorgestrel.
The first human trial with oral contraceptives was performed in
1956, and the first licensed use for birth control was in 1959, the cul-
aunation of nearly 40 years of research that began with animal experi-
ewits of ovarian transplantation in 1921 in Innsbruck (22). Since the
!~wst use. changes in the composition of oral contraceptives have con-
°cnied the oestrogen dose and the progestogen compound. Enovid, the
foloral contraceptive in the USA, contained 150 μg mestranol. Over
"Kjears, the oestrogen dose has been reduced from 100-150 μg first to
** l*?· then to 30-35 μ§, while some oral contraceptives that are cur-
rently available contain only 20 μg ethinyloestradiol. For the progesto-
gen compound in combined oral contraceptives, change over time con-
cerned the chemical composition of the progestogen rather than the
dose. While the first oral contraceptives contained a first generation
progestogen, the second generation was used throughout the seventies,
and the third generation progestogens became widely used from the
mid-1980s onward (new oral contraceptives were introduced in differ-
ent countries at various times, e. g., oral contraceptives with a third
generation progestogen had a majority market share in Southern Europe
in the beginning of the 1990s, when they were only just entering the
market in the USA).
Currently, over a 100 million women worldwide use oral contracep-
tives (23). This widespread use by young and usually healthy women
indicates that even a rare deletenous effect could affect many women,
at an age when serious disease is infrequent. Serious cardiovascular
side effects of oral contraceptives are thrombotic events, including
venous thrombosis, myocardial infarction and stroke. In this review we
will mainly focus on venous thrombosis.
Older Studies on Risk of Venous Thrombosis and OCs
After the first report in 1961, more case reports followed rapidly.
A hallmark study, comparing women with thombosis to control women
without thrombosis (case-control study) was based on data recorded by
the Royal College of General Practioners (24). In this study, published
in 1967, it was found that oral contraceptives mcreased the risk of
thrombosis nearly 3-fold. Another British study found a relative risk
of 6 (25, 26), and two US studies yielded relative risks of 4 and 11
(27, 28). In the 1970s, large prospective follow-up studies were con-
ducted which confirmed the results of the case-control studies (29-31).
The risk estimates from studies published before 1990 are shown in
Fig. 1. Overall, the studies pointed to a 3-fold increased risk of venous
thrombosis in users of oral contraceptives (32). Several important attri-
butes of the risk emerged from these studies: the risk does not increase
with longer duration of use, and disappears immediately when oral con-
traceptives are discontinued, i.e., past-users do not have an increased
risk. Higher relative risks were found for idiopathic than for secondary
thrombosis (25-27,33).
Most of these studies were performed before objective testing for
venous thrombosis was possible or in widespread use. We know that a
substantial proportion of all clinical diagnoses of deep-vein thrombosis
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Fig. / The relative nsk
for \cnous thrombosis m
oral contraceptive use. The
relative risks (users vs. non-
users) are shown from stud-
les pubhshed betweert 1967
and 1989, with 95%-confi-
dence intervals. A relative
nsk of l indicates equal
risks, a relative risk excee-
ding one indicates a higher
risk for users than for non-
users. The studies include
case-control studies (24.
26-28, 46, 160-163), fol-
low-up studies (29-31, 165-
167) and one randomized
controlled trial (168). Some
figures were estimated from
data in the original papers
ed from substantial misclassification with regard to venous thrombosis.
Studies that divided diagnoses by level of certainty (e. g. '"defmite" vs.
"probable" vs. "possible") thrombosis, or those that focussed on
the more severe events, usually reported higher relative risk (25-27,30,
31, 36), which Supports the existence of misclassification. This sug-
gests that the risk of oral contraceptives is underestimated in the older
studies.
Recent Studies on Risk of Venous Thrombosis and OCs
Studies in the 1990s showed similar relative risk estimates to the
earlier studies with a two- to six-fold increased risk of venous throm-
bosis (37-40), while several studies published after 1995 showed a risk
differential by progestogen content (see below). The absolute risk of
venous thrombosis in women of reproductive age is estimated at 1-2 per
10,000 per year (l, 2,41). Data of Dutch national registries showed in-
cidence rates of all venous thrombotic events among young individuals
of 2 per 10,000 per year in those aged 15-24 years, and 4 per 10,000 per
year in those aged 25-39 (42). In another Dutch study, an annual inci-
dence for deep-vein thrombosis was reported of 0.8 per 10,000 among
women not using oral contraceptives, and 3.0 per 10,000 per year in
oral contraceptive users (37). A similar rate of 2.0 per 10,000 among
users of oral contraceptives was reported for women in the United
Kingdom (43). In absolute terms, these risks do not seem large. On
the other hand, since oral contraceptives are used by large numbers of
women, their use is responsible for the majority of all venous throm-
botic events in young women (44).
Referml Bias
Some have sought to explain the absence of a reduction of the risk of
thrombosis associated with the use of oral contraceptives since the
1960s by so-called referral or diagnostic suspicion bias. The idea is that
physicians would, when consulted by a woman with complaints that
could point to thrombosis, preferentially refer those who used oral
contraceptives for further diagnostic tests. This would lead to an over-
estimate of the frequency of oral contraceptive use among thrombosis
patients, and subsequently an overestimate of the risk when these pa-
tients were compared to a randomly selected control group of women
without thrombosis. Two studies have demonstrated that this bias does
not explain the currently observed risk estimates (45, 46). In these
studies. women referred for diagnostic tests for thrombosis and who
subsequently tested positive, were compared to women referred for the
same reason but who tested negative. Because patients and controls
were referred under the same suspicion of thrombosis, referral and
diagnostic suspicion bias were eliminated. Relative risks associated
with oral contraceptive use were 6.4 (45) and 3.9 (46), i. e., very similar
to recent studies with population controls.
Effect ofOestrogen Dose
Since the early use of oral contraceptives the oestrogen dose has gra-
dually been decreased, from 100-150 μ§ ethinyloestradiol or mestranol
in the first brands, to 50 and 30 μσ, and recently even to 20 μg ethinyl-
oestradiol. The expected result of this change was a reduction in the
incidence of cardiovascular side effects. Such a trend is not obvious
when the risk estimates found in studies published from the 1960s to the
1990s are evaluated, äs Fig. l shows: the risks do not appear to have
decreased over tirne. However, such a time-trend, or the absence of it
may be deceiving because of other changes that occurred over time.
such äs improvements in diagnostic methods. In several studies, a lower
risk for oral contraceptives with a lower oestrogen content was found
(31, 36,47). In the most recent of these, the risk of venous thrombosis
was increased over 10-fold (compared to non-users) for oral contracep-
tives containing more than 50 μg ethinyloestradiol, and 4-fold for
those containing less than 50 μg ethinyloestradiol (47). Reports from
several other studies, however, did not identify a difference between
oral contraceptives by oestrogen dose (16, 30, 39, 48). In the Leiden
Thrombophilia Study, a direct comparison of oral contraceptives con-
taining either 30 μg or 50 μg ethinyloestradiol, and the same second
generation progestogen (levonorgestrel), showed 3- to 4-fold increased
risks for both oestrogen dosages compared to non-users (16).
It seems plausible from the available literature that the earliest COB-
traceptives containing 100 μg or more ethinyloestradiol conferredi
higher risk of venous thrombosis than current formulations containW|
50 μσ or less. It remains highly questionable whether the further red*'
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vn in 'H μί ethinyloestradiol led to a further lowering of risk, while
•.vre are no data at all suggesting a lower risk of the newest oral con-
s containing only 20 μg ethinyloestradiol.
ί ΎΙ/ <i/ Progestogen Content
-\i ihe end of 1 995, three studies simultaneously reported an increas-
;d nsk ot \enous throrabosis in women who used oral contraceptives
»ith the progestogens desogestrel or gestodene ("third generation con-
inkepmes'") (16-18). Subsequently, more than 10 studies have re-
r-fled on this issue, most of which confirmed that oral contraceptives
-oniaming desogestrel or gestodene had an increased nsk of throm-
N-MS 1 43. 46. 49-53), while some did not (54-57). Fig. 2 shows the
Minute·. of non-commercially-sponsored studies (to reduce heteroge-
wn\ ot estimates [58, 59]), with a summary 95%-confidence interval
·-' j l 7- to 2.8-fold increased risk of third-generation versus second-
ieneration oral contraceptives. The risks are considerably higher during
ihe first \ear of use (60) and then might become äs high äs 3 per 1000
W \ear tor users of oral contraceptives containing a third generation
prugestogen (53).
These findings have led to considerable controversy and several
inherem biases were claimed to be present (61-66). These were said to
indude preferential prescription, diagnostic bias, attrition of suscep-
uWes. starter or healthy-user effects, effects of switching types of oral
contraceptives, and effects of different age distributions of the users
d ^anous oral contraceptive types. From reanalyses of previously
i*iblished data, and new studies, it was claimed that such biases were
ffesent (20. 55, 56, 67-69). Thus controversy has fuelled the debates
4·'. 70-73). It has been pointed out that commercial interests may have
ä'fected the debate (58, 59, 74, 75) and that "considerable sums of mo-
*) ha\e been spent in denigrating well conducted studies with both
c'ear hypotheses at the outset and clear analyses, studies which unex-
KttedK found that newer pills containing desogestrel and gestodene
*we associated with higher risks of venous thrombosis than older pre-
pafations with other progestogens. Often highly personalised attacks
"^e been made to discredit the work of well-respected researchers, re-
ΐΛ authorities. and the World Health Organisation" (76).
The various possible biases that have been proposed have been
carefully reviewed, and it was concluded that they could not explam the
observation of a higher thrombotic risk with oral contraceptives con-
taining the third generation progestogens desogestrel and gestodene
(77-79). An independent expert committee convened by the World
Health Organisation came to the same conclusion (80).
One of the original aims in developmg contraceptives with a third
generation progestogen was to reduce the risk of myocardial infarction.
An early study suggested such a beneficial effect (81), while other
studies did not (82, 83). Since each of these included fewer than
30 women with a myocardial infarction who used oral contraceptives
(and fewer than 10 who used third generation contraceptives), no con-
clusions could be drawn. A large study in the United Kingdom of more
than 400 women with a myocardial infarction at a young age, including
40 patients who used oral contraceptives (20 with a third generation
brand) yielded no evidence for a reduced risk (relative risk 1.8, 95%
confidence interval 0.7-4.8 for third versus second generation oral con-
traceptives) (84). 1t has been known for many years that oral contracep-
tives have a variety of metabolic effects, including effects on the
procoagulant, anticoagulant and fibrinolytic system (85, 86). These
changes were within the normal ränge and therefore considered of
little relevance, while it was also suggested that the pro- and antithrom-
botic effects might keep each other in balance (85, 86). In 1997, it was
first reported that third generation oral contraceptives had a different
and strenger procoagulant effect than second generation contraceptives,
in a test that quantified the response of plasma to activated protein C
(APC) on thrombin generation (87). In this test, the endogenous throm-
bin potential (ETP), which is defined äs the time-integral of free throm-
bin concentration, usually derived from residual levels of amilodytic
activity (a2M-IIa), is determined in the presence and absence of added
activated protein C, yielding an APC-sensitivy ratio (87). The major
difference of this EPT-APC-sensitivity ratio to the Standard APC-resis-
tance test (88, 89) is that initiation of coagulation takes place via the
extnnsic pathway by tissue factor, while the original test is based on
the APTT (87-89). The ETP-APC-sensitivity test proved effective in
detecting factor V Leiden, äs was the APTT-based APC-sensitivity test,
but showed much greater sensitivity to hormonal effects, which only
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led to mild changes m the APTT-based APC-sensiti\ity lest (90. 91) .
With this lest, a clear difference was found betw een users of second and
third generation contraceptives (87). From the results in individuals
with various factor V genotypes (Leiden or wildtype) and non-users
and users of various types of oral contraceptives. it was apparent that in
the ETP-APC-sensitivity lest, third generation oral contraceptives in-
duced a coagulation abnormality of about the same magnitude äs that
seen in carriers of factor V Leiden. This coincides with the approxi-
mately equal clinical effects. ie. a 7- to 8-fold increased risk of venous
thrombosis for carriers of factor V Leiden, and a 6- to 10-fold increased
risk of venous thrombosis in users of third generation oral contracep-
tives compared to women not using an oral contraceptive (77.87). This
study was criticised on design issues which led to a randomised cross-
over study, in which women volunteers used an oral contraceptive with
levonorgestrel (second generation progestogen) for a fixed period of
two cycles, and an oral contraceptive with desogestrel (third generation
progestogen) for two cycles. in a randomised order with a two-cycle
wash-out period in-between (92). In this study contraceptives were
compared on a large number of effects on procoagulant, anticoagulant
and fibrinolytic factors (92-95). First of all. the pronounced effect of
oral contraceptives containing desogestrel in inducing APC-resistance
was confirmed (92). Secondly, while levonorgestrel-contaming con-
traceptive increased factor VII. äs had been reported earlier (reviewed
in [85, 86,96,97]). the increase was much larger with desogestrel-con-
taining contraceptive (12% vs. 32% increase) (93). Thirdly, deso-
gestrel-containing oral contraceptive led to a decrease in both total and
free protein S, while no effect of the levonorgestrel-containing oral
contraceptive was observed (95). Finally, in an analysis of fibrinolytic
Parameters, increased endogenous fibrinolytic parameters were ob-
served for both types of oral contraceptives. which was, however, not
accompanied by a change in clot lysis time, suggesting that the increas-
ed fibrinolytic activity during oral contraceptive use was counterba-
lanced by TAFI-mediated down-regulation of fibrinolysis (94). This
down-regulation of fibrinolysis, which is factor XI-independent, was
more pronounced with the desogestrel-than with the levonorgestrel-
containing contraceptive (94). The Overall picture from these studies is
that oral contraceptives with a third generation progestogen affect the
haemostatic system in a more pronounced way than contraceptives with
a second generation progestogen, in a direction that is prothrombotic. It
has been been demonstrated in the Leiden Thrombophilia Study that
APC-resistance äs established by the enogenous thrombin potential
(ETP-APC-sr) is a strong predictor of venous thrombosis. which clini-
cally validates the results of the laboratory studies with this lest (98).
Effect ofOther Risk Factors
In women with deficiencies of natural anticoagulant proteins, i.e.,
protein C, protein S or antithrombin, high risks of venous thrombosis
have been found among oral contraceptive users. In selected families
with familial thrombophilia due to these deficiencies, annual risks
among oral contraceptive users ranged from 6-27 percent, with the
highest risk in antithrombin deficient women (99). In female relatives
of unselected patients with these deficiencies, oral contraceptive use
also increased the risk of thrombosis. by 6- to 8-fold (100) over above
the thrombotic risk brought about by the thrombophilic defect.
Several studies have shown that APC-resistance is common (10-37
percent) among women who developed thrombosis during oral contra-
ceptive use (50. 101, 102). In two population-based studies a high risk
was found for factor V Leiden carriers who used oral contraceptives, in-
dicating 20- to 30-fold increased risks compared to women without
factor V Leiden who did not use oral contraceptives (37. 54). In a com-
parison of unselected relatives wi th \arious thrombophilic defects, the
synergistic effect with oral contraceptives appeared even higher for
deficiencies of natural anticoagulants than for factor V Leiden (100).
The interaction of oral contraceptives with factor V Leiden was most
strikmg for those using a third-generation progestagen (16). Homozy-
gosity for factor V Leiden leads to a 50- to 100-fold increased risk of
venous thrombosis (103). In a series of homozygous patients, 80 per-
cent of the women with thrombosis had been using oral contraceptives,
which suggests a very high risk of oral contraceptives in these women
(104).
The prothrombin 20210 G to A variant, which by itself increases the
risk of thrombosis 2- to 4-fold (105) also interacts synergistically with
oral contraceptives, with a 16-fold increased risk of thrombosis in
carriers who used oral contraceptives compared to non-carrier non-
users (54).
High levels of factor VIII are, like factor V Leiden and prothrombin
2021OA. common in the general population and may therefore affect
many individuals (106, 107). The combination of high levels of factor
VIII and use of oral contraceptives was associated with a 10-fold in-
crease in risk compared to individuals with lower levels (<150 lU/dl)
who did not use oral contraceptives. This estimate did not exceed the
sum of the separate effects of the two risk factors (108).
The synergistic effects with oral contraceptives on the occurrence of
deep vein thrombosis of factor V Leiden and prothrombin 2021 OA, and
deficiencies of protein C, protein S and antithrombin, are also present
for thrombosis at unusual sites. The risk of cerebral vein thrombosis
was highly increased in women with either factor V Leiden or pro-
thrombin 20210A who used oral contraceptives (109,110).
Screeningfor other Risk Factors
When other factors enhance the risk of oral contraceptives, consid-
eration could be given to screening for abnormalities prior to prescrip-
tion. Theoretically, screening may offer benefit if the joint effect of the
two risk factors exceeds the sum of the separate effects, in which case
withholding oral contraceptives from the high-risk group would leadto
a larger reduction of thromboses than random withholding (111). For
deficiencies of protein C, protein S and antithrombin, it is obvious that
the population prevalence is too low to render screening for these
abnormalities worthwhile. This may be different for factor V Leiden
and prothrombin 2021 OA, each of which has a population prevalence of
several percent. Some have argued that the risks of thrombosis, even in
the presence of such a genetic defect and oral contraceptive use, are still
small in absolute terms (less than 3 per 1000 per year), and that there-
fore the number of women needed to screen to prevent one fatal throin-
boembolism is very high (112, 113). Others have taken a more pro-
active view towards screening, citing äs a reason the severe morbidity .
that may follow non-fatal thrombotic events, e.g. the postthrombotic
syndrome (114). It is important to realise that the issue of screening
involves other issues than thrombosis morbidity and mortality, but also
psychological effects, social effects (e. g. Insurance problems). and
finally, cost. Data balancing all these various aspects are currentl)
lacking, and in the absence of convincing data screening cannot be re-
commended.
Biological Mechanism
Over the last few years major advances have been made in under- · j
Standing why oral contraceptives cause thrombosis. Numerous publica- l
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ommistrated effects of oral contraceptives on the haemo- Composition and Types of HRT
1 1 5 - 1 1 8 ) . Effects include increases in procoagulant^ ,\.lein (9l. l!
\|| uoior.X. factor XII and factor XIII, reductions in the antico-
J .(. pr. nein S and antithrombin, and an increase in the fibrinolytic
•η p'l t-minnuen (reviewed in [85, 86, 96]). The net effect is an
.--.f-J \PC-resbtance with coagulation activation and thrombin
n .ΐΗ)-93. 95). which is not counterbalanced by the increased
tk actmt) (94)· It is not clear how oral contraceptives exert
*gif unou^ biochemical effects on the molecular level. i.e., what
ftc t> plavd b\ the hormone receptors, or how the oestrogen and
ttfiS.w amipounds interact in bringing about these effects. Since
Ή-ft'i) ihromboMs is a multicausal disease, the development of throm-
^«HS in an oral contraceptive user will be the result of interactions with
,ΐίχτ πΛ taciors. such äs the genetic make-up of the woman (16, 119).
l: ru> K'cn vho\\ n that the haemostatic system of some women, the
»HillcJ In per-responders, is more sensitive to exposure to oral con-
TATr><i>^ than that of others, and it is plausible that these women are
u tashiM i>k of dexeloping thombosis (120).
i,u i'· \nmalDisease
()r,il umtraceptives also increase the risk of myocardial infarction,
iiN reported m 1963 (121), of ischaemic stroke, first reported in 1968
•"'!. and ot haemorrhagic stroke, first reported in 1973 (122). A recent
*id\ h\ the World Health Organisation showed a 5-fold increased risk
N* imocardial infarction (83). This, and other studies reviewed in the
;i»S WHO Report on cardiovascular disease and oral contraception
•5*)ι confirmed a high risk in women with major cardiovascular risk
iwon». m particular smoking and hypertension. The recent study by the
Äorld Health Organisation on ischaemic stroke showed a 3-fold in-
creised n-k associated with the use of oral contraceptives (123), and a
IS- to 2-fold increased risk of haemorrhagic stroke (124).
Hormone Replacement Therapy
and Early Results
PiWmenopausal Hormone Substitution has been used for several
toade«, (125. 126). While in the 1970s only a few percent of post-
wnopausal women used Hormone replacement therapy. it became
*idespread m the 1990s (11-13, 125). The early indication was relief
^ menopausal Symptoms, but more recently it was suggested that hor-
üwne replacement therapy could confer other benefits, affecting major
Jheaiies. This was based on the observation of the more rapid progres-
*n ot osteoporosis and development of cardiovascular disease in
»Omen after menopause. It was hypothesised that hormone replace-
wnt therapy would reduce the development of osteoporosis and the
iflcidence of fractures, and lower the incidence of cardiovascular disease,
"β particular myocardial infarction. Observational studies in the early
I98(X confirmed these effects (127-133). For cardiovascular disease,
wipressive risk reductions were reported, with a halving of the risk of
iardio\ascular events and cardiovascular death (129, 130), and even a
«milar risk reduction for all-cause mortality (131). It was also shown.
6°*e\er. that women who used hormone replacement therapy often
*! a different cardiovascular risk profile than non-users. and that
*Mion bias offered an alternative explanation for the apparent bene-
•||M 134-136), To resolve this matter, several randomised. controlled.
ι have been performed or are in progress.
Early hormone replacement therapy consisted of an oestrogen only
(oestrogen replacement therapy, ERT. also referred to äs unopposed
hormone replacement therapy). Because of the strong evidence that
unopposed oestrogen therapy increased the risk of endometrial cancer
(reviewed in [126]), nowadays oestrogen-only hormone replacement
therapy is restricted to women after hysterectomy, while. for women
with an intact Uterus, a progestogen compound, e.g. medroxyproge-
sterone acetate, is added. Conjugated oestrogens used in oral prepara-
tions are distilled from urine of pregnant mares. Micronised oestradiol
and oestradiol-valerate that is hydrolised to oestradiol is also available
in tablets (137). Alternatively, oestradiol raay be delivered trans-
dermally (patches). percutaneously by gels, subcutaneously by pellets
every six months and rarely. nasally. It is generally thought that the
oestrogen dose in hormone replacement therapy is lower than in oral
contraceptives. It should be noted, however. that comparing the
effective doses of different compounds from very different origins with
different clinical assays, is problematic.
Risk of Veiwus Thrombosis
In the first systematic study of adverse effects of hormone replace-
ment therapy, in 1974, a slight excess of oestrogen users was reported
among patients with venous thrombosis compared to healthy controls
(14% versus 8%). Subsequent studies failed to find an association
(138-140) and in commentaries it was authoritatively stated that the
notion that oestrogen replacement therapy could cause venous throm-
bosis was based on "medical superstition" (141). In 1996, a number of
studies showed that the risk of venous thrombosis was increased in
users of hormone replacement therapy (l 1-13, 142). These four obser-
vational studies reported relative risks for current users between 2. l and
3.6 compared to non-users. These, and subsequent studies that con-
firmed the association between hormone replacement therapy and
venous thrombosis (143-147) included case-control studies and
prospective follow-up studies, concerned deep vein thrombosis äs well
äs pulmonary embolism. and dealt with idiopathic and secondary
thrombosis. In most studies, the risks were highest in the first year of
use (11, 12, 143. 144. 147), with a complete restriction to the first
year in some studies (143, 144, 147), while in other studies the risk
also remained elevated after several years of use ( 1 1 , 146). Elevated
thrombotic risks were found for users of oral äs well äs users of trans-
dermal hormone Substitution (143, 144) and for conjugated oestrogens
äs well äs for oestradiol (143, 147).
One may wonder why the early studies did not detect a risk, while in
recent studies hormone replacement therapy was shown to increase
venous thrombotic risk, which even was of the same magnitude äs the
relative risk brought about by oral contraceptives. One explanation is
the lack of objective diagnostic testing for venous thrombosis in the
older studies. A misclassification that would result in the inclusion of
many individuals in the case-group who are actually not suffering from
thrombosis. thereby diluting the effect. It is not implausible that the
high oestrogen doses in oral contraceptives led to a high risk of throm-
bosis which was detectable in studies performed with unreliable diag-
nostic methodology, which lacked the accuracy to detect the risk
brought about by hormone replacement therapy. A second explanation
is the low prevalence of use of hormone replacement therapy at the
time of the early studies, which led to a low power to detect differences
in risk. In the Boston Collaborathe Drug Surveillance Program, the
117
Thromb Haemosi 2001; 86: 112-23
frequency of hormone Substitution was 8% in the control population
and 14% (age-standardised) among the patients. which would yield a
relative risk estimate of nearly two. with wide confidence intervals
smce the prevalences were based on only 18 women with venous
thrombosis (125). Interestingly. the only recent study that did not find
an association between hormone replacement therapy and the risk of
venous thrombosis. also had a low frequency of use among the healthy
population, of 5 to 6 % (139). In contrast, in most of the other studies
well over 25% of control women used hormone Substitution (11-13,
147), up to 50% in the randomised trial (146).
Of special interest is a randomised trial among women with prior
venous thrombosis (137). This study was terminated when other studies
pointed to an increased thrombotic risk with hormone replacement
therapy (11-13, 145) and showed a high rate of recurrence of 8.5 per-
cent per year in the treatment group (versus l. l percent per year in the
placebo group) (137).
Risk of Arterial Thrombosis
While observational studies have suggested a clear benefit of hor-
mone replacement therapy for the development of arterial disease, this
has not been borne out by a randomised trial, rendering further credibil-
ity to the self-selection of women with a better cardiovascular risk pro-
file amongst users of hormone replacement therapy. The Heart and
Estrogen/progestin Replacement Study (HERS) was a secondary pre-
vention trial, in which over 2500 women with prior coronary disease
were randomised to receive either hormone Substitution or placebo
(148). Over the five year duration of this trial, in which an excess of
venous thrombosis was observed (145,146), no benefit with regard to
arterial disease could be demonstrated (RR = 1.0, CI95 0.8-1.2). Post-
hoc analyses suggested a pattern of early härm and late benefit, with
rate ratios of 1.5 in the first year, and 0.75 in the fourth and fifth year of
use (148). The Women's Health Initiative (149) is a large on-going pla-
cebo-controlled primary prevention trial in which nearly 30000 women
have been enrolled. In the first two years of this large study, an excess
of both myocardial infarction and venous thrombosis was observed in
the treatment group (150).
Effect of other Risk Factors
The high risk of venous thrombosus during early phases of use sug-
gests, äs for oral contraceptives (151), that there is a subgroup of
women with a genetic predisposition to thrombosis who are at particu-
lar risk when exposed to hormone replacement therapy. The results of
HERS indicate that this is also likely to be the case for arterial disease
(148). In the study of hormone replacement after prior venous throm-
bosis, the majority of women who experienced a recurrence had genet-
ic (factor V Leiden) or acquired (anti-cardiolipin antibodies) predispo-
sition (137). In a re-analysis of the Oxford case-control study (11), a
high risk of thrombosis was observed in women who were resistant to
APC (152). In a subsequent genetic analysis, we found that, while the
presence of a prothrombotic mutation (either factor V Leiden or pro-
thrombin 20210A) increased the risk of thrombosis 4.5-fold, and the
use of hormone replacement therapy increased the risk 3.6-fold, the
combination of these two risk factors led to an 11-fold increased risk.
This suggests a synergistic effect (Rosendaal, unpublished data).
Recently, it was reported that in women with a prothrombotic gene
defect (prothrombin 20210A), hormone replacement therapy increased
the risk of myocardial infarction. The effect of this therapy was most
pronounced among hypertensive women (11-fold increase), while
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women without the prothrombotic variant had no increased risk of
myocardial infarction when using hormone Substitution (153). A study
has been started to investigate women who develop thrombotic events
during the first year of the primary prevention trial (WHI) for suscep-
tible subgroups due to genetic abnormalities.
Biologie Effect s
Hormone replacement therapy affects many biological parameters.
In a randomised trial (Postmenopausal Estrogen/Progestin Interven-
tions Trial, PEPI) it was shown to improve lipoprotein profile and
decrease plasma fibrinogen (154). In the same study a decrease of so-
luble E-selectin was seen (155). which was in line with the decrease of
another soluble marker of inflammation, ICAM, in another study (156).
However, results from the PEPI trial also showed an increase in C-
reactive protein. which renders the effects of hormone Substitution on
inflammation difficult to Interpret (155). Effects on coagulation are
similar to those of oral contraceptives, with evidence for coagulation
activation, increased APC-resistance. increased factor VII, decreased
antithrombin, and increased fibrinolytic activity by a decrease in PAI-1
(157) (reviewed in [158]), although the effects are not consistent among
studies (159). The effects on inflammation markers, äs well äs on
several coagulation parameters (factor IX, APC-ratio, PAI-1, t-PA)
were only seen with oral hormone replacement therapy and not with
transdermal patches (156,160).
Conclusion
Oral contraceptives increase the risk of venous thrombosis at all
oestrogen dosage formulations. This risk does not seem to have been
lowered much, if at all, by dose reductions below 50 ^g ethinyloestra-
diol, and is also influenced by the type of progestogen, i.e., so-called
third generation progestogens (desogestrel and gestodene) increase the
risk further. Oral contraceptives also increase the risk of myocardial
infarction and stroke. In absolute terms, except for first-time users in
the first year of use, these increases in risk are small. Therefore, the
probability of complications need not outweigh the benefits of oral con-
traceptives, or compare unfavourably to the complication rates of other
methods of birth control. Obviously, once an oral contraception is
prescribed, the safest one should be used, especially since all mono-
phasic combined oral contraceptives have equal efficacy and minor
side-effect frequencies. Therefore, there is no place for third generation
contraceptives, unless other contraceptives are poorly tolerated and
provided the woman is informed about the increased thrombotic risks.
Even though there is little doubt that the risk of thrombosis is greatly
enhanced in the concomittant presence of prothrombotic abnormalities,
such äs the frequently occurring factor V Leiden and prothrombin
2021OA, no case can yet be made in favour of indiscriminate screening
for these abnormalities prior to prescription. While obtaining Informa-
tion on a family history of venous thrombosis seems useful, it is also
unclear whether a positive family history should lead to screening with
selective withholding of oral contraceptives, or other policies (such äs
withholding oral contraceptives in all women with a positive family
history). A personal history of thrombosis is a contra-indication for oral
contraceptive use.
Hormone replacement therapy has been shown to ameliorate:^
Symptoms of menopause, and to reduce the progression of osteoporo-.,|
sis, but has not produced the expected reduction in cardiovasculsfs|
disease. It increases the risk of venous thrombosis, and has, in the only |̂
randomised trial so far of women with prior coronary disease, nÄ^
Rosendaal et al.: Hormones and Thrombosis
A«ii an ou'rall benefit. It is yet to be determined if subgroups of
• Nihle uomen can be identified, so that in future the therapy can
v »i'hhiU l'rnni women whom it might härm, and be prescribed to
t, 'u-r, w h > > r n n would benefit.
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